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ABSTRACT 
 
Phospholamban (PLB) inhibits the activity of cardiac calcium pump (SERCA2a). We previously showed 
that PLB with engineered Cys-residues only cross-linked to the Ca2+-free, E2 intermediate of SERCA2a. 
The formation of E2•PLB prevents Ca2+ binding at the high affinity Ca2+ binding sites and blocking the 
enzyme kinetic cycle.  Here we further studied synergistic action of PLB and ATP on E2 in prevention of 
forming the phosphorylated E2P-like states stabilized by metal fluorides.  SERCA2a was co-expressed in 
insect cell microsomes with PLB mutants of normal or super-inhibitory strength, with cross-linkable 
mutations at either cytosolic (N30C) or luminal (V49C) sides of PLB. For normal strength PLB mutants, 
in the absence of nucleotide, metal fluorides totally inhibited both SERCA2a enzyme activity and cross-
linking of PLB to SERCA2a at both sites, suggesting that PLB dissociated from SERCA2a in the E2P-
like states. However, at the same condition, super-inhibitory PLB mutants prevented total enzyme 
inhibition by metal fluorides.  Further, the cross-linking of super-inhibitory PLB to SERCA2a was only 
partially inhibited by metal fluorides, but was drastically restored upon sequential addition of ATP. These 
results revealed the equilibrium between E2•PLB, E2•ATP, or E2•ATP•PLB states and E2P-like states, 
suggesting that the synergistic binding of ATP and PLB to SERCA is very strong, sufficient to prevent 
formation of E2 phosphoenzymes, even when stabilized by metal fluorides. 
 
INTRODUCTION 
Phospholamban (PLB1), a 52 amino acid, single-transmembrane domain protein, inhibits the Ca2+-
ATPase (SERCA2a isoform) in cardiac SR [1, 2] by decreasing its apparent affinity for Ca2+ ions.  
Phosphorylation of PLB at Ser16 (by cAMP-dependent protein kinase A) or Thr17 (by calmodulin kinase 
II) partially reverses enzyme inhibition, thus increasing SR Ca2+ uptake at low ionized Ca2+ 
concentrations [1] and augmenting cardiac contractile forces [1]. The anti-PLB monoclonal antibody 
2D12 prevents WT-PLB/SERCA2a heterodimer formation, fully reversing WT-PLB inhibition of 
SERCA2a [3-5].  
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SERCA pumps Ca2+ into the SR (ER) lumen through a complex catalytic cycle [6-8](Fig. 1). Two 
Ca2+ ions bind to the high Ca2+ affinity binding sites at the cytoplasmic face of SR (ER) (E1•Ca2). 
Autophosphorylation at Asp351 and subsequent transition into low Ca2+ affinity E2 phosphoenzyme 
release 2 Ca2+ into the lumen, before dephosphorylation of E2 phosphoenzyme occurs to form the low 
Ca2+ affinity E2 dephosphoenzyme [9].  The E2 phosphoenzyme intermediates are sensitive to Ca2+ and 
ATP [10], but can be stabilized by various SERCA inhibitors.  For example, metal fluorides (MFs) BeFx, 
AlFx, and MgFx are known to mimic inorganic phosphate and stabilize SERCA1a in the discrete E2P-like 
conformations, specifically the ground E2P state, the transition E2~P state, and the product E2•Pi state, 
respectively [9-15] (Fig 1).  In addition, VD or TG stabilizes SERCA in transition E2~P state or the 
ground E2 state, respectively [9].  Recently, 3D crystal structures for several of these conformations were 
resolved for SERCA1a (See reviews in [6-8]).       
We proposed that among the entire catalytic cycle, PLB interacts with a unique E2 state of SERCA2a 
[4, 16-19]. The formation of E2•PLB slows the enzyme transition to E1, thus competing for Ca2+ binding 
to E1, and thereby decreasing the apparent Ca2+ affinity of SERCA2a for Ca2+.  This model is based on a 
series of studies, in which we showed that cross-linking of PLB to SERCA2a at both cytoplasmic and 
transmembrane domains with an array of cross-linkers only occurs in the Ca2+ free states, but is 
completely inhibited by micromolar Ca2+ [16, 20-23], Pi [16], TG [16, 17, 20, 22], VD [17], or 2D12 [4]. 
Thus, PLB does not associate with SERCA2a through the entire catalytic cycle [24], but has to 
completely dissociate from E1, E2•TG or E2•VD.  Consistent with this idea, super-inhibitory PLB 
mutants were shown to have much higher binding affinity for E2, thus super-shifting the Ca2+-dependent 
ATPase activity [17, 23].  Further, we recently obtained a 3D crystal structure of SERCA1a with bound 
PLB (E2-PLB)[25], which is formed in the Ca2+-free condition in a detergent system that preserves 
SERCA activity and its interaction with PLB.  Although sharing a globally similar structure with the 
E1•Mg state [26, 27], E2-PLB has collapsed Ca2+ binding sites that are devoid of divalent cations, 
confirming the cross-linking results and the mutually exclusive binding of PLB and Ca2+ to the enzyme. 
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One of our early findings is that PLB4, the most potent super-shifting PLB mutant, and ATP 
synergistically stabilize E2 that is remarkably resistant to SERCA inhibitors, including TG and VD [16, 
17].  However, due to TG interaction with multiple conformations of SERCA, Ca2+-dependent ATPase 
activity assay is not suitable for further functional characterization.  On the other hand, the effect of less 
potent SERCA inhibitors, MFs, on SERCA2a activity remains largely uninvestigated, with only a few 
earlier reports, in which PLB was shown not to affect interactions between fluoride and SERCA2a [28, 
29]. 
Here, using insect cell membranes with co-expression of SERCA2a and PLB mutants with increasing 
inhibitory strength, we evaluated effects of MFs on physical interactions between PLB and SERCA2a at 
both cytosolic and luminal sides, as well as on functional Ca2+-dependent ATPase activity.  Possible 
mechanism of synergistic PLB and ATP binding to E2 is discussed.  
 
RESULTS 
Effect of metal fluorides on Ca2+-dependent ATPase activity of cardiac SR membranes —   As shown 
in Fig. 2A, in the absence of both Ca2+ and nucleotide, a 10 min pre-incubation with MFs at 
concentrations reported for saturating inhibition for SERCA1a [9, 10] totally inhibited SERCA2a activity 
in the canine cardiac SR membranes in the low micromolar Ca2+ concentration range, suggesting the 
irreversible stabilization of the E2P-like states by MFs.  At greater than 10 µM Ca2+ concentrations, 
samples pre-treated with BeFx showed some recovery in the Ca2+-dependent ATPase activity (diamonds).  
This ability of Ca2+ to restore activity was reported for SERCA1a previously [10] and attributed to the 
fact that the E2•BeFx state can bind luminal Ca2+ at the low Ca2+ affinity site, leading to its destabilization 
at high Ca2+ concentrations [30].   Thus, MFs appear to have similar effect to inhibit the activity of both 
SERCA2a and SERCA1a. 
To determine if PLB interferes with MFs inhibition of SERCA2a, we compared the effect of 2D12 on 
the MFs concentration-dependent inhibition of  SERCA2a activity in cardiac SR membranes (Fig. 2B).   
A higher concentration of MFs is required to inhibit SERCA2a activity in the absence of 2D12 when PLB 
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is bound.  Addition of 2D12 shifted the dose-dependent inhibition curves to the left (compare open to 
closed symbols), decreasing Ki values for MFs (Table 2).  These results demonstrate for the first time that 
PLB protects against MFs inhibition of SERCA2a activity.  
Identical experiments were also conducted using insect cell membranes co-expressing SERCA2a and 
PLB.  Relative to SERCA2a expressed alone, co-expression of WT-PLB shifted the dose-dependent MFs 
inhibition of SERCA2a enzyme activity to the right, significantly increasing Ki values (Table 2).  Thus, 
similar to that for native PLB in cardiac SR membranes, co-expression of WT-PLB in insect cells 
protected against MFs inhibition of SERCA2a activity. 
The effect of PLB mutants of different inhibitory strength on metal fluorides inhibition of SERCA2a     
— To determine if super inhibitory PLB mutants provide better protection, we co-expressed WT-
SERCA2a with normal inhibitory strength N30C-PLB, or super-inhibitory strength PLB4 [17] in insect 
cells.  Both PLB mutants contain a Cys mutation at Asn30 of PLB in cytoplasmic domain IB, which cross-
links highly specifically to Lys328 of SERCA2a in the phosphorylation domain [17].  In addition, we also 
co-expressed V89C-SERCA2a with normal inhibitory strength V49C-PLB, and a new super-inhibitory 
PLB mutant PLB4C-term, both containing a Cys mutation at Val49 of PLB, to study the interactions 
between the two proteins at the opposite (intra-luminal) face of the SR membrane.      
As expected, Fig.3 shows that relative to SERCA2a co-expressed with PLB of normal inhibitory 
strength (N30C-PLB or V49C-PLB), gain-of-function PLB mutants (PLB4 and PLB4C-term) super-
shifted the Ca2+-dependent curves of SERCA2a activity far to the right (upper panels, See table 1 for KCa 
values).  Similar to that occurred in the cardiac SR membranes (Fig. 2A) and insect cell membranes with 
co-expression of WT-PLB and SERCA2a, saturating concentration of MFs completely inhibited Ca2+-
ATPase activity of SERCA2a with co-expression of N30C-PLB or V49C-PLB (Triangles).  In sharp 
contrast, in the presence of the same saturating concentration of MFs and absence of nucleotides and 
Ca2+, PLB4 and PLB4C-term partially restored SERCA2a activity.  Specifically, at high µM Ca2+ 
concentrations, SERCA2a co-expressed with PLB4C-term or PLB4 retained about 60-80% of maximal 
Ca2+-dependent ATPase activity against inhibition by MFs (Squares).  These results demonstrate that 
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PLB super-shifters protect against inhibition of SERCA2a even at saturating concentrations of MFs.  
Cross-linking of PLB to SERCA2a was next examined to see if effects of MFs on PLB binding to 
SERCA2a and on Ca2+-dependent ATPase activity are correlated.   
The effect of metal fluorides on PLB cross-linking to SERCA2a — As shown in Fig. 4A, in the 
absence of nucleotide and Ca2+, MFs pre-incubation in these samples completely inhibited cross-linking 
of N30C-PLB to Lys328 or V49C-PLB to V89C of SERCA2a, respectively.  The identical results were 
obtained with TG, forming the irreversibly inhibited dead end complex (E2•TG)[16, 22].  These results 
suggest that PLB does not interact with these E2P-like states stabilized by MFs at both cytoplasmic and 
transmembrane domain of PLB.     
In contrast, in the presence of MFs, PLB4 and PLB4C-term retained the ability to cross-link to 
SERCA2a (Fig 4B).  Cross-linking was strongest in the presence of MgFx, and somewhat lower in the 
presence of AlFx or BeFx, which qualitatively correlate well with the PLB super-shifters protection of 
SERCA2a enzyme activity (Fig. 3).  These results demonstrate that these PLB super-shifters remain able 
to form E2•PLB even in the presence of MFs.  
Metal fluorides concentration curves on the PLB cross-linking to SERCA2a and the enzyme activity 
—As shown in Fig. 5, in the absence of Ca2+ and nucleotide, MFs inhibited both the cross-linking of 
N30C-PLB or V49C-PLB to SERCA2a and the Ca2+-dependent ATPase activity in a correlated 
concentration-dependent manner (open symbols)(Table 3).  These results suggest that the binding of PLB 
and MFs to SERCA2a are competitive.  Further, dose-dependent inhibition of Ca2+-dependent ATPase 
activity and cross-linking for PLB4 or PLB4C-term to SERCA2a were also correlated (Fig 5, red solid 
symbols).   Importantly, compared to that for the regular inhibitory strength PLB, the MFs dose response 
curves for Ca2+-dependent ATPase activity and cross-linking of super-inhibitory PLB to SERCA2a were 
significantly shifted to the right, strongly suggesting that higher PLB binding affinity for SERCA2a 
increased formation of E2•PLB and decreased MFs inhibition of SERCA2a.  
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Effect of nucleotide ADP or ATP on metal fluorides inhibition of PLB cross-linking to SERCA2a — 
Although the two assays yielded consistent results, one of the major discrepancies is the use of ATP, 
which is present in the Ca2+-dependent ATPase assay but absent in the cross-linking assay.  Note that 
nucleotide, ADP or ATP, is known to disrupt the formation of E2P by MFs [11] and promotes formation 
of PLB binding E2•Nuc conformation [16, 17, 20, 22].  We thus added ADP or ATP sequentially 10 
minutes after samples incubation with MFs, and then measured both cross-linking of PLB to SERCA2a 
and Ca2+-dependent ATPase activity.  In the case for normal inhibitory strength PLB mutants, the Ca2+-
dependent ATPase activity assay revealed that MFs totally inhibited enzyme activity in these samples 
even after sequential addition of ADP or ATP (Fig. 6A, upper panels). This is also consistent with results 
that cross-linking of PLB and SERCA2a was almost completely inhibited (Fig. 6B, upper panels). 
Therefore, normal inhibitory strength PLB does not interact with these E2P-like states stabilized by MFs, 
regardless of ATP or ADP binding to these states [9].  In addition, these results suggest that once formed, 
these MFs-induced E2P-like states were stable, yet different from the E2•Nuc, E2•PLB, or E2•Nuc•PLB 
state [16, 22].  Thus, formation of the E2P-like states by MFs inhibited Ca2+-ATPase activity and at the 
same time prevented E2•Nuc•PLB formation even in the presence of N30C-PLB or V49C-PLB.       
In the case for PLB super-shifters (Fig. 6A & B, lower panels), when ADP or ATP was sequentially 
added after samples incubation with MFs, PLB4 and PLB4C-term preserved 60-80% and 50-70% of 
SERCA2a activity, respectively. Remarkably though, in contrast to that for the effect of N30C-PLB or 
V49C-PLB, sequential addition of ADP or ATP after samples incubation with MFs significantly 
increased percentage of cross-linking of SERCA2a to PLB4 or PLB4C-term (Fig. 6B, lower panels, 
+ADP or +ATP vs -Nuc). After sequential addition of ADP or ATP, the cross-linking of SERCA2a to 
PLB4 or PLB4C-term in MFs significantly increased from 40-65% to 70-95% or from 30-45% to 60-92% 
of the controls, respectively.  For MgFx, cross-linking of SERCA2a to PLB4 or PLB4C-term was reached 
above 90% of the maximal intensity after sequential addition of ADP or ATP.  Note that although very 
faint, addition of ADP or ATP weakly restored cross-linking of normal inhibitory strength V49C-PLB to 
V89C-SERCA2a in the presence of MgFx (Fig. 5B,).  These results suggest that the binding of PLB super 
Competition between PLB and MFs binding to E2 
8 
 
shifters, which has profound long-range conformational effects on both the cytoplasmic domains and the 
transmembrane domain previously shown to prevent E1•Ca2 [17], synergistically promotes nucleotide 
binding and formation of E2•Nuc•PLB, giving ATP the ability to recover SERCA2a previously inhibited 
by MFs.   
ATP concentration curves on the PLB cross-linking to SERCA2a — We observed that in conditions 
when either nucleotide and MFs are simultaneously added, or nucleotide first and then MFs are 
sequentially added, MFs inhibition of both SERCA2a enzyme activity and cross-linking to PLB was 
drastically reduced (data not shown), showing that ADP or ATP protects SERCA2a from MFs inhibition 
in these conditions as it was previously demonstrated for SERCA1a [11].  We examined ATP dependency 
in stimulation of cross-linking of PLB to SERCA2a in these samples with simultaneous incubation of 
ATP and MFs.  The presence of MFs significantly shifted the curves of ATP stimulation of PLB cross-
linking to SERCA2a to the right (Fig. 7), yielding a 5-10 fold increase in the KATP values (Table 4).  
These results suggest MFs reduced the amount of E2•ATP•PLB complex and decreased the apparent ATP 
affinity for SERCA2a in these conditions. Moreover, compared to that occurred for N30C-PLB or V49C-
PLB, in the presence of MFs, ATP stimulation curves of cross-linking for PLB4 and PLB4C-term to 
SERCA2a were all significantly shifted to the left (Fig. 7), yielding much smaller KATP values (Table 4).  
In the case for the strongest super-shifting mutant PLB4, MFs only marginally shifted the curves, 
suggesting that ATP may not be necessary for E2•PLB4 to resist MFs binding to the pump.  These results 
suggest that increased inhibitory strength of PLB and ATP synergistically promotes formation of 
E2•ATP•PLB, thus preventing the formation of E2P-like states in the presence of MFs.   
DISCUSSION 
In this study, using cardiac SR membranes and insect cell microsomes co-expressing PLB and 
SERCA2a, we biochemically examined the effect of MFs on the molecular interactions between 
SERCA2a and PLB, in the presence and absence of ATP.  Our results demonstrate that synergistic 
Competition between PLB and MFs binding to E2 
9 
 
binding of PLB and ATP to E2 protects against enzyme inhibition and prevents formation of E2•Pi, 
E2~P, or E2P states, even when stabilized by MFs.  
Reversible binding of PLB to SERCA2a —  In addition to noted difference to E1 [25], the structure of 
E2-PLB is also different from any other E2 structures crystallized in the presence of SERCA inhibitors, 
e.g, MFs or TG [7, 8]. In particular, in E2-PLB structure, the global rearrangement of M2, M4, M6 and 
M9 forms a groove that fits PLB binding [25].  However, when SERCA1a is stabilized with MFs, the 
groove becomes almost flat, thus unable for PLB to dock.  These structural differences are compatible 
with the present study, in which we showed that the inhibition of both SERCA2a activity and PLB cross-
linking to SERCA2a at both faces of SR membranes are highly correlated in a MFs concentration-
dependent manner (or amount of stabilized E2P-like states) (Fig. 5), and is influenced by the inhibitory 
strength of PLB.  These results lead to the conclusion that when SERCA2a is stabilized in E2P-like states 
by MFs, the entire PLB molecule must completely dissociate from the enzyme (Fig.4).  Therefore, as 
SERCA2a transits from E2P to E2 and then to E1•Ca2, PLB must be able to bind specifically to E2 and 
then dissociate from E1•Ca2.   
E2•ATP and dephosphorylation process for E2P — Early biochemical studies reveal that the SERCA 
reaction cycle consists of at least 5 distinct low Ca2+ affinity E2 states, including E2•ATP, E2, E2•Pi, 
E2~P, or E2P (Fig. 1).    As recently shown by Clausen et al [9], ATP is capable to bind at the modulatory 
site to all these E2P states, but with different affinity.  These authors suggest that the ATP stabilization of 
the transition and product states, which have relative high affinity for ATP, is involved in E2 
phosphoenzyme dephosphorylation process [9].  However, we showed that the apparent ATP affinity, 
tested by ATP stimulation of PLB cross-linking to SERCA2a in the presence of MFs (Fig. 7), remains 
similar for all these E2P-like states.  Further, we showed that ADP acts similarly to ATP in protection of 
enzyme activity and formation of E2•ADP•PLB.  Since it is well established that these E2P-like states are 
insensitive to ADP [10], binding of ATP to these E2P-like states appears not to be the sole reason for the 
acceleration of dephosphorylation of E2P, at least for SERCA2a.  Instead, among these E2 states for 
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SERCA2a, E2•ATP appears to be a more thermodynamically favorable state that is involved in 
promoting stimulation of H+/Ca2+ cation exchange and enzyme transition into E1•Ca [31], as well as 
dephosphorylation of E2 phosphoenzyme. 
An advantage of our approach is the use of 2D12, which specifically removes PLB interaction with 
SERCA2a [3-5], thus unmasking the protective effect of PLB.  Hawkins et al showed that 
phosphorylation of PLB did not alter the sensitivity of SERCA2a to inhibition by fluorides [29].  
However, phosphorylation of PLB introduced ATP, which itself affects fluorides inhibition.  Another 
advantage of our approach using PLB as a specific probe is that we correlate the Ca2+-dependent ATPase 
activity assay (requiring addition of ATP, Ca2+, and Ca2+ ionophore A23187), with the cross-linking of 
PLB to SERCA2a (occurring in the Ca2+-free condition), making it possible to test directly the 
equilibrium between E2•ATP, E2, and E2P-like states.  We showed that ATP and PLB act independently 
and synergistically against formation of E2P-like states.  Thus, the mechanism by which nucleotide [11, 
15] or PLB protects SERCA inhibition by MFs from can be attributed to the promotion of E2•Nuc or 
E2•PLB formation.   Further, although PLB binds to both E2 with and without ATP binding at the 
modulatory site, E2•ATP, an intimate part of the SERCA kinetic cycle, might be the physiological 
conformation that favors PLB binding and forming a more stable complex.  Finally, based on the 
similarities in biochemical properties between E2•ATP and E2•PLB, we propose that E2•PLB or E2•ATP 
have similar structural motifs (e.g., favoring formation of both a binding grove for PLB at the 
transmembrane domain and a binding pocket for ATP in the N-domain), allowing PLB and ATP to 
interact synergistically to stabilize E2•PLB•ATP, which most strongly competes against binding of other 
inhibitors (e.g., MFs [11], TG [17, 32], VD [17, 33]).  This hypothesis can ultimately be proved by 
resolving 3D crystal structure of these conformations, particularly for SERCA2a.     
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EXPERIMENTAL PROCEDURES 
Preparation of canine cardiac SR membranes— The study protocol was approved by the Indiana 
University Institutional Animal Use and Care Committee and conforms to the Guide for the Care and Use 
of Laboratory Animals. Cardiac microsomes enriched in SR (45,000 x g pellets) were prepared from the 
left ventricles of dog hearts as previously described [34].  There is a roughly 1:1 molar stoichiometry 
between PLB and SERCA2a in these SR membranes [19, 35].  
Mutagenesis and Baculovirus Production—Mutagenesis of canine SERCA2a (V89C-SERCA2a) and 
PLB cDNAs was conducted directly in the transfection vector pVL1393 using the QuickChangeTM XL-
Gold system (Stratagene) [16, 17, 22].  N30C-PLB and V49C-PLB was made on the Cys-less PLB 
background, which is fully functional, with Cys residues 36, 41, and 46 changed to Ala.  PLB4 is a 
quadruple (N27A, N30C, L37A, V49G) mutant on WT-PLB background [17].  PLB4C-term has 
mutations at N27A, N30A, L37A, and V49C on WT-PLB background.  All mutated cDNAs were 
confirmed by DNA sequencing of the plasmid vectors.  Baculoviruses encoding mutated proteins were 
generated with BaculoGoldTM (Pharmingen) linearized baculovirus DNA [16, 17, 22].   
Protein Expression — Co-expression of SERCA2a and PLB proteins in Sf21 insect cells was 
achieved by baculoviruse infection and was quantified with the monoclonal antibodies 2A7-A1 and 2D12, 
respectively [4, 36].  Microsomes were harvested 60 h after infection and stored frozen in small aliquots 
at -40 ºC at a protein concentration of 6-10 mg/ml in 0.25 M sucrose, 10 mM MOPS (pH 7.0).  Protein 
concentration was measured by the Lowry assay.  Membranes co-expressing PLB and SERCA2a at a 
molar ratio in a range of 1:1 to 4:1 were used for current studies. All PLB mutants used in this study were 
predominantly monomers on 15% SDS-PAGE as noted previously [16, 17, 20, 22].  
Formation of E2P-like states by MFs— microsomes were incubated for 10 min at room temperature 
in buffer A (40 mM MOPS (pH 7.0) and 75 mM KCl) with 1 mM EGTA and MFs.   MFs were used to 
stabilize various intermediate forms occurring during the E2P dephosphorylation reaction sequence.  The 
MgFx product state was formed in 5mM MgCl2 and 5mM NaF.  The AlFx transition state was formed in 
0.2mM MgCl2, 2mM NaF, 0.5 mM AlCl3.  The BeFx ground state was formed in 0.2 mM MgCl2, 2mM 
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NaF, 0.1 mM BeSO4. These conditions are used to produce saturating inhibition of SERCA1a [9, 10].  In 
some experiments, diluted MFs were used as indicated.                       
Cross-linking— The heterobifunctional thiol-to-amine cross-linking reagent, KMUS (Pierce), or 
homobifunctional thiol-to-thiol cross-linking reagent, bBBr, was used to cross-link of residue N30C of 
PLB to Lys328 of SERCA2a, or V49C of PLB to V89C of SERCA2a, respectively, as described 
previously [16, 22].  Prior to cross-liking, 11 µg of microsomal protein was incubated for 10 min at room 
temperature with MFs in 12 µl of buffer A and 1 mM EGTA.  In some experiments, 3 mM ADP or ATP 
was included in the buffer before, together, or 10 minute after incubation with MFs as indicated.  Cross-
linking reactions were started by adding 0.75 µl of KMUS or bBBr from 1.6 mM stock solutions in 
DMSO (0.1 mM final cross-linker concentrations), and terminated by adding 7.5 µl of 15% SDS sample 
buffer containing 100 mM dithiothreitol.  Cross-linking reactions time was 10 min for KMUS or 1hr for 
bBBr.  Samples were then subjected to SDS-PAGE followed by immunoblotting with anti-PLB 
monoclonal antibody, 2D12, to detect PLB cross-linked to SERCA2a.  Antibody visualization was 
routinely with 125I-protein A followed by phosphorimager quantification (BioRad personal Fx).  Data 
analysis was done with Origin (Microcal).  In some experiments, concentrations of ATP or MFs were 
varied, as indicated.  TG was added from stock solutions in ethanol.     
Ca2+-ATPase Activity Assay— Ca2+-dependent ATPase activities of microsomes were measured using 
an enzyme-coupled spectrophotometric assay [18, 23]. The rate of NADH decay was measured at 340 nm 
in a SPECTRAmax® PLUS (Molecular Devices) microplate spectrophotometer at 37 °C. Assay buffer 
contains buffer A, supplemented with 3mM MgCl2, 5 mM NaN3, 3 µg/ml of the Ca2+ ionophore, A23187, 
3 mM ATP and Ca2+/EGTA buffer.  The final concentration of EGTA was fixed at 1 mM, and ionized 
Ca2+ concentrations were set by adding CaCl2 from 0 to 1.25 mM.  For assay at a full range of Ca2+ 
concentration, 70 µg membranes was incubated in 40 µl of buffer A, 1mM EGTA, and MFs as described 
in the above section.  Some membranes were pretreated with 2D12 to dissociate PLB [4].  In some 
experiments, 3 mM ADP or ATP was included in the buffer, or added after incubation with MFs as 
indicated. After incubation, samples were diluted to 280µl with buffer A (final EGTA concentration was 
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0.25mM).  Assay was started by adding 20µl (5µg) protein to 130 µl assay buffer in each well.  All 
ATPase activities reported are Ca2+-dependent. 
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Table 1.  KCa values for Ca2+ activation of Ca2+-ATPase activity.   
 
SERCA2a was expressed alone or co-expressed with PLB in insect cell microsomes.  Ca2+-ATPase 
activities were then measured as indicated in Figs. 2, and 3.  Maximal Ca2+-ATPase activities ranged 
between 10 and 15 µmol of ATP hydrolyzed/mg of protein/h for insect cell microsomes co-expressing 
PLB and SERCA2a [17]. All KCa values are expressed in units of µM.  Results are the means ± S.E. from 
3-6 determinations.   
 
 
 
 
 
 
Table 2.  Ki values for MFs inhibition of Ca2+-ATPase activity.   
 
SERCA2a was expressed alone or co-expressed with PLB in insect cell microsomes.  Ca2+-ATPase 
activities were then measured as indicated in Figs. 2 and 5.  All Ki values are expressed as concentrations 
for 50% inhibition of maximal Ca2+-ATPase activity obtained in the absence of MFs (see Experimental 
procedures).  Results are the means ± S.E. from 3-6 determinations.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                 KCa values 
proteins Control 2D12 
                       µM  
Cardiac SR 0.30 ± 0.02 0.13 ± 0.01 
          
WT-SERCA2a 0.15 ± 0.01 0.17 ± 0.04 
+WT-PLB 0.35 ± 0.03 0.22 ± 0.02 
       + N30C 0.36 ± 0.03 0.22 ± 0.01 
       + PLB4 1.48 ± 0.18 0.59 ± 0.07 
   
V89C-SERCA2a 0.14 ± 0.01 0.16 ± 0.02 
       + V49C 0.39 ± 0.02 0.23 ± 0.02 
       + PLB4C 0.89 ± 0.08 0.36 ± 0.02 
                  Ki values 
proteins MgFx  AlFx BeFx 
                                                              µM  
Cardiac SR 2500 ± 50 120 ± 10 35 ± 1 
           + 2D12 1850 ± 140 80 ± 11 26 ± 2 
    
WT-SERCA2a 2010 ± 200 115 ±15 18 ± 2 
       + WT-PLB 2900 ± 250 170 ± 10 26 ± 3 
           + 2D12                  2300 ± 150 120 ± 10 17 ± 2 
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Table 3.  Ki values for MFs inhibition of Ca2+-ATPase activity and cross-linking of PLB to 
SERCA2a.   
 
SERCA2a was co-expressed with PLB in insect cell microsomes.  Ca2+-ATPase activities and cross-
linking to PLB were then measured as indicated in Fig. 5.  All Ki values are expressed as concentrations 
for 50% inhibition of maximal activity obtained in the absence of MFs (see Experimental procedures).  
Results are the means ± S.E. from 3-6 determinations.   
 
 
 
 
 
 
 
Table 4.  KATP values for ATP stimulation of cross-linking of PLB to SERCA2a.   
 
SERCA2a was expressed alone or co-expressed with PLB in insect cell microsomes.  ATP effects on 
cross-linking to PLB were then measured as indicated in Fig. 7.  All KATP values are expressed as 
concentrations for 50% stimulation of maximal activity obtained in 3 mM ATP.  Results are the means ± 
S.E. from 3-6 determinations.  N.D., not determinable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                                                    Ki values 
                Ca2+-ATPase Activity    Cross-linking  
proteins MgFx  AlFx BeFx MgFx  AlFx BeFx 
                                                                                             µM  
 WT-SERCA2a + N30C 3100 ± 300 145 ± 15 23 ± 2 1400 ± 150 180 ± 15 14 ± 1 
       
V89C-SERCA + V49C 3650 ± 250 165 ± 30 26 ± 3 1700 ± 150 135 ± 10 11 ± 1 
       KATP values 
proteins Control MgFx  AlFx BeFx 
                          µM  
WT-SERCA2a     
    + N30C 7.8 ± 0.4 68.0 ± 19.0 68.5 ± 4.8 91.3 ± 10.2 
    + PLB4 16.5 ± 9.9 7.4 ± 2.5 17.3 ± 2.0 8.9 ± 1.6 
     
V89C-SERCA2a     
    + V49C N.D. 42.3 ± 4.1 105.8 ± 25.6 68.0 ± 11.0 
    + PLB4C-term N.D. 34.7 ± 7.7 30.6 ± 8.6 37.1 ± 7.0 
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FIGURE LEGENDS 
FIGURE 1.  Reaction cycle of SERCA.   
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FIGURE 2.  MFs inhibition of Ca2+-dependent ATPase activity of cardiac SR membranes.  Canine 
cardiac SR membranes were first pre-incubated with (open symbols) or without (solid symbols) the anti-
PLB monoclonal antibody 2D12, and then incubated 10 min in the absence (Con, squares)  or presence of 
MgFx (circles), AlFx(triangles), or BeFx (diamonds).  Incubations were in the absence of both Ca2+ and 
nucleotide.  A. Ca2+-dependent ATPase activity was determined at saturating inhibition concentration of 
MFs.  Similar results were obtained in at least 3 experiments.  B.  MFs dose-dependent inhibition of Ca2+-
dependent ATPase activity.  Plot was normalized Ca2+-dependent ATPase activity based on at least 3 
experiments for each condition (see text for concentrations).  Ca2+-dependent ATPase activity was 
measured at 0.8 mM Ca2+ and 1 mM EGTA.  The percent of maximal activity (determined in the absence 
of MFs) was calculated at each MFs concentration. See Table 2 for Ki values. 
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FIGURE 3.  MFs inhibition of Ca2+-ATPase Activities of SERCA2a co-expressed with normal or 
super-inhibitory PLB mutants.  WT-SERCA2a was expressed alone or co-expressed with N30C-PLB, 
or PLB4 (left panels), and V89C-SERCA2a was expressed alone, or co-expressed with V49C-PLB, or 
PLB4C-term (right panels) in insect cell microsomes as indicated.  Ca2+-dependent ATPase activity was 
determined 10 min after pre-incubation in the absence (Con) or in the presence of MgFx, AlFx, or BeFx.  
Pre-incubation was in the absence of both Ca2+ and nucleotide.  Maximal Ca2+-ATPase activities ranged 
between 10 and 15 µmol of ATP hydrolyzed /mg of protein/h for insect cell microsomes co-expressing 
PLB and SERCA2a.  The percent of maximal activity (determined in the absence of MFs) was calculated 
at each Ca2+ concentration for each PLB mutant.  See Table 1 for KCa values.   
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FIGURE 4.  MFs inhibition of cross-linking of normal or super-inhibitory strength PLB mutants to 
SERCA2a.  WT-SERCA2a was co-expressed with N30C-PLB, or PLB4 (left panels) and V89C-
SERCA2a was co-expressed with V49C-PLB, or PLB4C-term (right panels) in insect cell microsomes as 
indicated.  Membranes were incubated in 1mM EGTA in the absence (Con) and presence of MgFx, AlFx, 
or BeFx, before cross-linking reaction as indicated.  Reactions were in the absence of nucleotides.  N30C-
PLB or PLB4 was cross-linked to Lys328 of SERCA2a for 10 min using KMUS while V49C-PLB or 
PLB4C-term was cross-linked to V89C-SERCA2a for 60 min using bBBr in buffer containing 40 mM 
MOPS (pH 7.0), 3.2 mM MgCl2, 75 mM KCl, (see EXPERIMENTAL PROCEDURES).  Reactions were 
stopped by adding SDS plus dithiothreitol, then samples were subjected to SDS-PAGE followed by 
immunoblotting with anti-PLB antibody, 2D12, followed by 125I-protein A.  PLB/SER, PLB cross-linked 
to SERCA2a;  PLB1, PLB monomers.  For economy of space, only PLB cross-linked to SERCA2a is 
displayed in B. 
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FIGURE 5.  MFs dose response curve for inhibition of SERCA2a activity and PLB to SERCA2a 
cross-linking.  SERCA2a was co-expressed with PLB mutants in insect cell microsomes and cross-linked 
as described in the legend to Fig. 4.  A.  Plot shows the Ca2+-dependent ATPase activity determined 10 
min after pre-incubation in the absence both Ca2+ and nucleotide  and in the presence of a series 
concentrations of MgFx (circles), AlFx(triangles), or BeFx (diamonds).  To obtain maximal Ca2+-
dependent ATPase activity, assays were performed at 0.8 mM Ca2+ and 1 mM EGTA for SERCA2a co-
expressed with N30C-PLB and V49C-PLB, at 1.25 mM Ca2+ and 1 mM EGTA for SERCA2a co-
expressed with PLB4, or at 1.1 mM Ca2+ and 1 mM EGTA for V89C-SERCA2a co-expressed with 
PLB4C-term.  B. Dose dependent inhibition of cross-linking of PLB to SERCA2a. Upper panels show 
representative immunoblots of cross-linking for each PLB mutant to SERCA2a after 10 min pre-
incubation in the absence of both Ca2+ and nucleotide,  and in the presence of a series concentrations of 
MgFx, AlFx, or BeFx.  Lower panels plots MFs inhibition of cross-linking for each mutant on a percentage 
basis (n = 4- 6 for each mutant).  The percent of maximal activity (determined in the absence of MFs) was 
calculated at each MFs concentration for each PLB mutant.  See Table 3 for Ki values.  
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FIGURE 6.  Nucleotide effect on MFs inhibition of cross-linking of PLB to SERCA2a.  SERCA2a 
was co-expressed with PLB mutants in insect cell microsomes and cross-linked as described in the legend 
to Fig. 4. Samples were pre-incubated 10 min in 1mM EGTA and in the absence (Con) and presence of 
saturating concentrations of MgFx, AlFx, or BeFx, in various conditions as indicated:  -Nuc, incubation 
with MFs in the absence of nucleotide;  Sequential, incubation with MFs was followed by incubation with 
3mM ADP or ATP.  A. Bar graph shows the Ca2+-dependent ATPase activity, measured at 0.8 mM Ca2+ 
and 1 mM EGTA for SERCA2a co-expressed with N30C-PLB and V49C-PLB, at 1.25 mM Ca2+ and 1 
mM EGTA for SERCA2a co-expressed with PLB4, or at 1.1 mM Ca2+ and 1 mM EGTA for V89C-
SERCA2a co-expressed with PLB4C-term.    B. Cross-linking of normal and super-inhibitory strength 
PLB to SERCA2a.  Each panel shows representative immunoblots of cross-linking for each PLB mutant 
and bar graph of MFs inhibition of cross-linking for each mutant on a percentage basis (n = 4- 6 for each 
mutant).  The percent of maximal activity (determined in the absence of MFs and in the presence of 3mM 
ATP) was calculated at each condition for each PLB mutant. 
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FIGURE 7.  MFs effects on ATP stimulation of PLB to SERCA2a cross-linking.  SERCA2a was co-
expressed with PLB mutants in insect cell microsomes and cross-linked as described in the legend to Fig. 
4.  Representative immunoblots show cross-linking for each PLB mutant to SERCA2a after 10 min 
incubation in the presence of MFs and a series concentration of ATP as indicated at the top.  Plots show 
MFs inhibition of ATP-stimulation of cross-linking for each mutant on a percentage basis (n = 4- 6 for 
each mutant).  See Table 4 for KATP values.  
 
 
